WO1997032868A1 - Nouveaux derives iridoides et inhibiteurs de la neovascularisation contenant ces derives en tant qu'ingredients actifs - Google Patents
Nouveaux derives iridoides et inhibiteurs de la neovascularisation contenant ces derives en tant qu'ingredients actifs Download PDFInfo
- Publication number
- WO1997032868A1 WO1997032868A1 PCT/JP1997/000675 JP9700675W WO9732868A1 WO 1997032868 A1 WO1997032868 A1 WO 1997032868A1 JP 9700675 W JP9700675 W JP 9700675W WO 9732868 A1 WO9732868 A1 WO 9732868A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- atom
- pyran
- physicochemical properties
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Definitions
- the present invention relates to a novel imide derivative and an angiogenesis inhibitor containing the derivative as an active ingredient.
- the present invention relates to a novel irilide derivative and a dish tube formation inhibitor containing the derivative as an active ingredient.
- Angiogenesis occurs in the normal physiological state of humans or animals, such as embryonic development, ovulation or placenta formation during the female cycle, healthy processes such as wound healing, inflammation and other repair processes, while the capillaries occur. It is known to occur in a number of pathological conditions, such as a rapid increase in blood vessels and serious damage to tissues. For example, N. Engl. J. Med. 285: 1182, 1971 describes that tumor cell proliferation occurs depending on increased capillary neovascularization of tumor tissue. In addition, Matsubara et al. In Inflammation Vol. 10, No.
- angiogenesis other diseases associated with an abnormal increase in angiogenesis include diabetic retinopathy in the ophthalmology field, posterior lens fibroplasia, angiogenesis associated with corneal transplantation, cataract, eye tumor, and tracho- Hemangiomas and fibrous hemangiomas in the pediatric area, hypertrophic scars and granulation in the surgical field, rheumatoid arthritis and edema sclerosis in the medical field, and atherosclerosis in heart diseases And various tumors are known.
- anti-rheumatic drugs used for the treatment of rheumatoid arthritis have an inhibitory effect on angiogenesis.
- antirheumatic agents include SH compounds such as sodium gold thiomaleate, auranoiin or D-vesicillamine.
- the above-mentioned drugs having an angiogenesis inhibitory action have various clinical problems.
- tetrahydrocortisol needs to be used in combination with heparin, which has an angiogenesis-promoting effect, in order to exhibit an angiogenesis-inhibiting effect.
- many of the above-mentioned antirheumatic drugs having angiogenesis inhibitory action have serious side effects, and thus are difficult to apply in drug administration.
- the present invention has been made in view of the above circumstances, has a remarkable inhibitory effect on angiogenesis without serious side effects, and is used for treatment and treatment of various diseases accompanied by abnormal increase in angiogenesis.
- a novel compound having an angiogenesis inhibitory activity useful for prevention and an angiogenesis inhibitor containing the compound as an active ingredient are provided. Disclosure of the invention
- the present inventors have conducted intensive studies on compounds having an angiogenesis inhibitory action in order to solve the above-mentioned problems, and as a result, have newly found a novel compound having an angiogenesis inhibitory action and completed the present invention.
- the present invention is as follows.
- X is a () alkyl group or -C0R 1
- R 4 may be the same or different, and each represents one or more of a hydrogen atom, a (—) cycloalkyl group, a fuunyl group, and one or more nitrogen, oxygen, or sulfur atoms as a hetero atom.
- Y is a hydrogen atom
- R 2 and R 3 may each be the same or different
- R y is an ( ⁇ ) alkyl group (unsubstituted or fi-substituted with halogen) or a phenyl group), or
- R 2 and R 3 combine to form a heterocyclylalkyl group or a heterocycloalkenyl group, and the heterocycloalkyl group and the heterocycloalkenyl group are such that R 2 and R 3 have a hetero atom.
- Z is (C ⁇ o) alkyl group [unsubstituted or hydroxyl group, a halogen atom, - 0- R 1 0, -OCO- R U, - 0C00- R 12 or -? 0C0NH-R 13 (R 10 ⁇ [1 3 is a group substituted by a hydrogen atom or a (C 5 ) alkyl which may be substituted with a halogen atom] or -CO-R 14 or -CH 2 -S-R 15 (R 14 and !?
- 15 can contain one or more nitrogen, oxygen or sulfur atoms as a heteroatom, may be condensed with a benzene ring, may be a 5- or 6-membered ring residue, or may have a hydroxy (C G) which may be substituted with an alkyl group).
- Y represents the same as described above, and R 16 represents a hydroxyl group, a methoxy group, or —0 ⁇ ( ⁇ 0 ⁇ is a pharmacologically acceptable salt, or ⁇ is an alkali metal atom).
- a new ylide derivative represented by ⁇ is a new ylide derivative represented by ⁇ .
- angiogenesis inhibitor containing as an active ingredient a novel sulfide derivative or a mixture thereof according to any of the above (1) to (10).
- FIG. 1 is an explanatory diagram showing the migration state of cells under a microscope in a cell migration inhibition (CMA) test.
- CMA cell migration inhibition
- novel sulfide derivatives represented by the general formulas (I) to (X) of the present invention can be produced as in the following (1) to (75).
- the compound (4b) can be obtained by separating the stereoisomers of the epoxide when obtaining the above (4a).
- This (4b) can be converted into an ester (7b) and a sodium salt (6b) by the same method.
- the compound (12) is converted from didinipine known per se through several steps. After alkylating the formyl group of (12), the generated hydroxyl group is reductively removed, and the compound (13) is produced by converting the ethoxyquinethyl group to a carbamoyl group and oxidizing the double bond.
- Compound (14) is produced from genipin known per se through several steps.
- Compound The compounds (), (16) and (17) can be respectively produced by variously alkylating the hydroxyl group of (14).
- compound (19) can be produced by carbamoylating genipin to the primary hydroxyl group of epoxide (18).
- a compound of the formula (28) can be used to produce a compound of the formula (30) from the compound (28).
- Compound (31) can be produced by subjecting known lactolol to rubamoylation.
- Compound (33) can be produced by converting didinipine known per se into ethyl ester compound (32), followed by several steps of conversion.
- the compound (34) known per se can be converted to the compound (35) by subjecting the compound (34) to rubamoylation. After protecting the hydroxyl group of (34), alkali hydrolysis of the methoxycarbonyl group is performed! ⁇ , After the generated carboxyl group is protected by benzylation, the protecting group of the hydroxyl group is removed, and the generated hydroxyl group is subjected to carbamoylation. Further debenzylation gives compound (36).
- the compound (36) is amidated, the compound (37) is treated with sodium methoxide, the sodium salt (38) is further converted, and the carboxyl group is reductively converted to a methyl group.
- Compound (39) can be produced.
- Compound (43), compound (44), and the like can be produced by subjecting didinipine, which is known per se, to dybamoylation.
- Compound (46) can be obtained by subjecting compound (45) known per se to reductive deacetalization followed by deacetylation.
- the compound (47) can be produced by epoxidizing the compound (46) and further subjecting the compound (47) to a rubamoylation of the compound (47) to produce a compound (48).
- Compound (49) can be produced by reacting the compound with azolum sodium salt.
- the compound (50) can be produced by oxidizing the primary hydroxyl group of the compound (46) obtained above to a carboxyl group and then amidating it.
- Compound (51) can be produced by oxidizing the primary hydroxyl group of the previously obtained compound (46) to formyl group, and then conducting a carbon enrichment reaction, and hydrogenating the resulting double bond. Oh.
- Compound (46) can be converted to compound (52) by subjecting it to rubamoylation, and the compound (53) can be produced by catalytic reduction of (52).
- the compound (54) can be produced by protecting the hydroxyl group of the compound (46), hydrolyzing the methoxycarbonyl group to amidate, and then performing deprotection.
- the compound (55) can be produced by oxidizing the hydroxyl group of the compound (47) obtained above to a formyl group, and then hydrogenating the double bond obtained after carbonization.
- the carboxy group of the compound (2) known per se is hydrolyzed to protect the resulting carboxyl group. Further, the compound (66) can be produced by removing the ethoxyxetyl group under the condition of acid hydrolysis, converting the generated hydroxyl group into carbamoyl group, and then converting the ester to a carboxyl group.
- Compound (70) can be produced by subjecting compound (20) to a hydration reaction followed by tosylation and epoxidation.
- the compound (71) known per se can be converted to the compound (72) by two steps i of reduction and oxidation after the compound (71) is converted into a compound.
- Compound (73) can be produced by reducing the conjugated double bond of compound (11).
- Compound (74) or compound (75) can be produced from compound (28) or (34) known per se in several steps of conversion.
- acetylation for example, acetic anhydride, acetyl, etc. are used as acetylating agents, and as bases, for example, triethylamine, diisopropylethylamine, pyridin, lutidine, collidine, diazabicycloundecene, Amines such as 4-dimethylaminopyridine are used alone or as a mixture, and as solvents, organic halides such as chloroform and dichloromethane, which do not react with the reagents themselves, ethers, and tetrahydrofuran. It can be achieved by reacting ethers such as benzene, aromatic hydrocarbons such as toluene, etc. at 0 ° C to around room temperature for more than an hour.
- bases for example, triethylamine, diisopropylethylamine, pyridin, lutidine, collidine, diazabicycloundecene
- Amines such as 4-d
- any method may be used as long as it is a general acid hydrolysis.
- the acid used include hydrochloric acid, sulfuric acid, pyridium p-toluenesulfonate, acetic acid, boron trifluoride etherate complex, and hydrogen fluoride. It can be achieved by reacting in water or an organic solvent containing water at around 0 ° C to 100 ° C for 30 minutes or more.
- Any method may be used for the hydrolysis of the alkali metal salt, as long as it is a general hydrolysis of the alkali metal salt, using an alkali metal hydroxide such as sodium hydroxide, sodium hydroxide, lithium hydroxide, etc. This can be achieved by reacting in water or an organic solvent containing water, such as methanol, ethanol, or propanol, at 0 to around 100 ° C for 30 minutes or more.
- the oxidation of the double bond to the epoxy group may be carried out by any commonly used reaction.
- metabolic perbenzoic acid magnesium monoperoxyphthalate, peracetic acid, cumene hydroperoxide, t-butyl hydroperoxide, etc.
- An organic peroxide may be used, if necessary, in the presence of a commonly known buffer such as sodium hydrogen carbonate or hydrogen phosphate, or, if necessary, panazyl.
- a catalyst such as acetyl acetate, tungstic acid, molybdenum hexacarbonyl, etc.
- the solvent is an organic halide such as chloroform, dichloromethane, or an aromatic hydrocarbon such as benzene or toluene, or methanol.
- the reaction can be achieved by using alcohols such as ethanol at 0 ° C to room temperature for about 10 minutes or more.
- the oxidation of the hydroxyl group to the carbonyl group may be carried out by any method as long as it is a commonly used reaction, and using manganese dioxide, pyridium chromate chromate, chromium trioxide, dimethylsulfoxide-based oxide, etc. This can be achieved by using an aromatic hydrocarbon such as benzene or toluene, or an organic halide such as chloroform or dichloromethane as a solvent, and reacting the mixture at room temperature for at least 30 minutes.
- the oxidation of a formyl group to a carboxyl group may be carried out by any generally known method.
- Sodium chlorite, chromic acid, ruthenium oxide and sodium periodate are used as oxidizing agents, and if necessary, sodium hydrogen phosphate and sulfamic acid etc. This can be achieved by reacting in a solvent such as water, an alcohol, or a halide such as dichloromethane at 0 ° C. to near room temperature for 10 minutes or more.
- Hydrogenated aluminums such as lithium aluminum hydride, diisobutylaluminum hydride, bis (methoxetoxy) aluminum hydride and ethers such as ether, tetrahydrofuran, and dimethoxetane
- a solvent such as benzene, benzene or toluene in a solvent such as -80 ° C to room temperature for more than 10 minutes
- the primary deacetalization reaction often achieves its purpose by the action of a reducing agent under acidic conditions. Therefore, the conditions are not particularly limited as long as the method is suitable for the purpose.
- Lewis acids such as trimethylsilyltrifluoromethanesulfonate, boron fluoride ether complex, titanium tetrachloride, hydrochloric acid, and toluenesulfonic acid are described.
- a reducing agent such as hydrogen, sodium cyanoborohydride, or triethylsilane in the presence of a protonic acid such as It has been reported that it can. 5-3. Reduction of carboxyl group to methyl group
- Examples of the protecting group include silyl-based protecting groups such as t-butyldimethylsilyl group and t-butyldifuunylsilyl group, acetal-type protecting groups such as ethoxyquinethyl group, tetrahydroviranyl group, methoxethoxymethyl group, and acetyl. And a protecting group such as a benzoyl group.
- the introduction of the silyl-based protecting group can be performed by using a general silylating agent such as t-butyldimethylsilyl chloride, t-butyldiphenylsilyl chloride, or t-butyldimethylsilyl triflate.
- a general silylating agent such as t-butyldimethylsilyl chloride, t-butyldiphenylsilyl chloride, or t-butyldimethylsilyl triflate.
- a common organic solvent such as chloroform, dichloromethane, dimethylformamide, benzene, etc. This can be achieved by reacting at 30 ° C to around room temperature for 5 minutes or more.
- the introduction of the acetal-type protecting group is carried out by using vinyl ethers such as ethyl vinyl ether and divinyl silane and halides such as methoxymethyl chloride as reagents, and paratoluenesulfonic acid, camphorsulfonic acid, and sulfuric acid as catalysts.
- vinyl ethers such as ethyl vinyl ether and divinyl silane and halides such as methoxymethyl chloride
- paratoluenesulfonic acid, camphorsulfonic acid, and sulfuric acid as catalysts.
- Under acidic conditions using a compound such as, for example, or under basic conditions using disopropylethylamine, triethylamine, etc., dichloromethane, chloroform, benzene, toluene, ether, tetrahydrofuran, etc.
- acetyl-protecting group can be introduced by using acetyl, acetic anhydride, benzoyl chloride, benzoyl bromide, benzoic anhydride, or the like as a reagent according to the acetylation method described above.
- Methods for deprotection include hydrolysis using an acid (3 above), acid hydrolysis (2 above), catalytic reduction (5 above), and a method using a fluoride ion.
- the method used depends on the type of protecting group.
- Deprotection using fluoride ions can be performed, for example, by using tetra-n-butylammonium fluoride (TBAF), aqueous hydrofluoric acid, potassium fluoride, hydrogen fluoride / pyridine, hydrogen fluoride triethylamine, etc.
- TBAF tetra-n-butylammonium fluoride
- a solvent in a solvent such as tetrahydrofuran, acetonitrile, cyclohexane, etc., if necessary, coexist with fuynol, benzoic acid, etc. as a buffering agent. It can be achieved by reacting for more than one minute.
- Forced bamoylation is a method in which a raw alcohol is reacted with an isocyanate, or a raw alcohol is reacted with a chloroformate or the like to form an active ester, and then a primary or secondary amine is used as a nucleophilic displacing agent. It can be achieved by a method of reacting.
- the alkyl-substituted isocyanate corresponding to the target product is usually used in an amount of about 1 to 5 moles per mole of the starting alcohol, and triethylamine and diisopropyl are used as bases.
- Amines such as ethylamine, pyridine, lutidine, coridine, diazabicycloundecene, and 4-dimethylaminopyridine, alone or as a mixture, are 5 times the normal catalyst amount to 1 mole of the starting alcohol.
- reaction can be achieved by a reaction time of 30 minutes or more, and in this case, it may be possible to convert to a thiocarbamate by using thiosinate instead of isocyanate.
- the active ester compound is usually a chloroformate (for example, phenyl chloroformate, methyl chloroformate, etc.) in an amount of about 1 to 5 moles per mole of the starting alcohol, and a base such as triethylamine, Amines such as diisopropylethylamine, pyridine, lutidine, collidine, diazabicycloundecene, and 4-dimethylaminopyridine are used alone or in a mixture of usually about 1 mole per 1 mole of the starting alcohol.
- a chloroformate for example, phenyl chloroformate, methyl chloroformate, etc.
- a base such as triethylamine
- Amines such as diisopropylethylamine, pyridine, lutidine, collidine, diazabicycloundecene, and 4-dimethylaminopyridine are used alone or in a mixture of usually about 1 mole per 1 mole of the starting alcohol.
- a primary or secondary amine corresponding to the target substance is usually used in an amount of about 1 to 5 times by mole, and if necessary, triethylamine or diisopropylamine as a base.
- Amines such as tilamine, pyridine, lutidine, collidine, diazabicyclopentadecene, and 4-dimethylaminopyridine are used in an amount usually 5 times the amount of the catalyst to 1 mole of the starting alcohol, and dichloromethane, chloroform, and the like.
- a common organic solvent such as mouth form, benzene, toluene, ether, and tetrahydrofuran, which does not react with the reagent itself, the reaction is carried out at -40 ° C to around room temperature for 30 minutes or more. You can get the body.
- Esterification includes a method of condensing a starting carboxylic acid and an alcohol and a method of causing an alkylating agent to act on the starting carboxylic acid.
- reaction solvent a large excess of crude alcohol may also serve as the solvent.
- water or an intended ester may be used in the system by using an organic solvent azeotropic with water such as benzene or toluene. It may be done while removing.
- the reaction is preferably carried out at a temperature of from o ° C to a reflux temperature. This reaction is often performed for 30 minutes to 20 hours or more.
- an alcohol is used in an amount of usually about 1 to 5 moles per mole of the starting carboxylic acid, and dicyclohexylcarbodiimide, 2-chloro-1,3-dimethylimidazolyl is used as a condensing agent.
- dimethyl chloride, getyl chloride phosphate, dimethyl cyanophosphate, diphenylphosphoryl azide, etc. are used per 1 mole of the starting carboxylic acid, and triethylamine, diisopropyl as bases are used.
- Amines such as ethylamine, pyridine, lutidine, corridin, diazabicyclopentadecene, and 4-dimethylaminopyridine are used alone or in a mixture, usually about 1 to 5 moles per mole of the carboxylic acid. Volume, dichloromethane, chloroform, benzene, toluene, ether, tetrahydro In a common organic solvent such as furan, which does not react with the reagent itself, there is a method in which the reaction is carried out in a solvent at 0 ° C to around room temperature for 30 minutes or more.
- an alkylating agent such as dialkyl sulfate such as dimethyl sulfate or dityl sulfate, or an alkyl halide such as methyl iodide, benzyl bromide or n-hexyl iodide is used per mole of the starting carboxylic acid.
- dialkyl sulfate such as dimethyl sulfate or dityl sulfate
- an alkyl halide such as methyl iodide, benzyl bromide or n-hexyl iodide
- amines such as triethylamine, diisopropylethylamine, pyridine, lutidine, collidine, diazabincloundecene, and 4-dimethylaminopyridine.
- Alkali gold carbonate Alkali gold carbonate
- the amidation is usually carried out using about 1 to 5 times the molar amount of primary amine or Z-class carboxylic acid with respect to 1 mole of the starting carboxylic acid, and zinc carbodiimide, 1,3-dimethylimidazolinium chloride, getyl chlorophosphite, getyl cyanophosphate, diphenylphosphoryl azide, etc., usually from about 1 mol per mol of starting carboxylic acid Using a 5-fold molar amount, amines such as triethylamine, diisopropylethylamine, pyridine, lutidine, collidine, diazabicyclopentadecene, and 4-dimethylaminopyridine are used alone or as a mixture to make 1 mole of the starting carboxylic acid.
- amines such as triethylamine, diisopropylethylamine, pyridine, lutidine, collidine, diazabicyclopentadecene, and
- Alkylation of the hydroxyl group is carried out by using the alkylating agent of the above 8-2.
- an alkylating agent is used in an amount of about 1 to 5 moles per mole of the raw material alcohol, and as a base, a tertiary amine such as triethylamine, diisopropylethylamine, or alkali metal hydride. ⁇ etc. is usually used in an amount of about 1 to 5 times the molar amount of 1 mol of the starting alcohol, and is a common organic solvent such as dichloromethane, chloroform, benzene, toluene, ether, tetrahydrofuran, etc.
- the reaction can be achieved by reacting at 0 ° C.
- Alkylating agents such as alkyl copper complexes, alkyl alkali metals, alkyl alkaline earth metals, Grignard reagents, and alkyltriphenylphosphonium halides.
- Alkyl magnesium bromide such as magnesium bromide and n-pentyl magnesium bromide, etc.Alkyl magnesium bromide, etc., is usually about 1 to 5 moles per mole of the starting aldehyde.
- an alkylating agent a common organic solvent such as dichloromethane, chloroform, benzene, toluene, ether, tetrahydrofuran, etc.
- the reaction can be carried out in a solvent that does not itself react with the reagent at -78 ° C to around room temperature for 30 minutes or more.
- Alkylation using alkyl phosphonium halide is carried out in a solvent such as ether, tetrahydrofuran or tert-butanol in the presence of an alkyl lithium such as n-butyl lithium or a base such as potassium tertiary butoxide. It can be achieved by reacting from -78 ° C to around room temperature for 30 minutes or more.
- halogenating agent thionyl chloride, imide N-persuccinate, carbon tetrahalide, alkyl sulfonic acid halide, etc. are generally used in an amount of about 1 to 5 times per mole of the starting alcohol.
- the amount of tetrachloroammonium fluoride (TBAF) or triethylamine used as the base is usually about 1 to 5 moles per mole of the starting alcohol, dichloromethane, In a common organic solvent such as chloroform, benzene, toluene, ether, tetrahydrofuran, etc., react in a solvent that does not react with the reagent itself at 0 ° C to around room temperature for 30 minutes or more. Can be achieved.
- a common organic solvent such as chloroform, benzene, toluene, ether, tetrahydrofuran, etc.
- any known method may be used for conversion to sodium salt.
- sodium methoxide, sodium carbonate, sodium hydrogencarbonate and the like may be used to convert sodium salt into an alcohol such as methanol or ethanol. but it may also be mixed with an organic solvent), 0 ° C from it by connexion accomplished by stirring 30 minutes more at about room temperature c
- the administration form of the angiogenesis inhibitor containing the novel ylide derivative of the present invention as an active ingredient is not particularly limited, and can be appropriately selected as necessary.
- oral preparations such as tablets, capsules, granules, fine granules, powders or solutions, or parenteral preparations such as injections or suppositories can be mentioned.
- the angiogenesis inhibitor of the present invention can be administered orally.
- the weight of the active ingredient in the angiogenesis inhibitor of the present invention varies depending on the age, sex, weight, or degree of disease of the patient, but is usually in the range of 30 to 1000 mg per day for an adult. It is preferable to administer this dose in several divided doses a day.
- Oral ij can be prepared by using the present compound alone or in an ordinary manner using excipients such as starch, milk, sucrose, mannite, carboxymethylcellulose, corn starch or inorganic salts. it can.
- excipients such as starch, milk, sucrose, mannite, carboxymethylcellulose, corn starch or inorganic salts.
- binders, disintegrants, surfactants, lubricants, fluidity promoters, flavoring agents, coloring agents, flavors and the like can be appropriately selected and used.
- binder examples include starch, dextrin, gum arabic, gelatin, hydroxypropyl starch, methylcellulose, carboxymethylcellulose sodium, hydroxypropyl cellulose, crystalline cellulose, ethylcellulose, and polyvinylpyrrolidone.
- a macro goal can be exemplified.
- starch hydroxypropyl starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose, carboxymethylcellulose or low-substituted hydroxypropylcellulose can be used as the disintegration ⁇ fU.
- surfactant examples include sodium lauryl sulfate, soybean lecithin, sucrose fatty acid ester, and polysorbate 80.
- examples of the lubricant include talc, waxes, hydrogenated vegetable oil, sucrose fatty acid ester, magnesium stearate, calcium stearate, aluminum stearate, and polyethylene glycol.
- examples of the fluidity promoter include light caustic anhydride, dried aluminum hydroxide gel, synthetic aluminum gaterate, and magnesium maleate.
- angiogenesis inhibitor of the present invention can also be administered as a suspension, an emulsion, a syrup, or an elixir.
- dosage forms may also contain flavoring or coloring agents.
- the angiogenesis inhibitor of the present invention can also be administered as a parenteral agent.
- the weight of the active ingredient in the angiogenesis inhibitor of the present invention depends on the age, weight, and degree of the disease of the patient. Usually, it is in the range of 1 to 300 mg per day for adults, and it is preferable to administer this dose by intravenous injection, intravenous drip injection, subcutaneous injection or intramuscular injection.
- the present compound can be diluted with an appropriate diluent and used.
- a diluent generally, distilled water for injection, physiological saline, aqueous glucose solution, vegetable oil for injection, sesame oil, laccase oil, tide oil, corn oil, propylene glycol or polyethylene glycol can be used.
- the parenteral preparation may further contain a bactericide, preservative or stabilizer, if necessary.
- injectables are filled and frozen in vials and the like, water is removed by ordinary freeze-drying technology, stored as a freeze-dried product, and lyophilized immediately before use. Can be re-prepared and used.
- the injection may further contain a tonicity agent, a stabilizer, a preservative, a soothing agent and the like, if necessary.
- Other parenteral preparations include, for example, liquid preparations for external use, ointments and other suppositories for rectal administration, and these preparations can be manufactured according to conventional methods.
- the angiogenesis inhibitor of the present invention contains the present compound having an angiogenesis inhibitory activity as an active ingredient, and is extremely useful for improving a pathological process having a correlation with angiogenesis.
- it can be used to suppress the growth of tumor cells, treat inflammation, and suppress the growth of granulation.
- it is widely applied to the treatment of diseases having a correlation with angiogenesis.
- n-tetrapylammonium fluoride 1.0 M tetrahydrofuran solution
- the reaction mixture was extracted with ethyl acetate.
- the organic phase was washed with saturated aqueous sodium hydrogen carbonate and saturated saline, and then treated with magnesium sulfate. Dried with Nesium.
- reaction mixture was poured into a saturated aqueous solution of sodium thiosulfate and extracted with ethyl acetate.
- organic phase was washed with a saturated saline solution, and then dried using magnesium sulfate.
- the organic phase was washed with 2N aqueous hydrochloric acid, saturated aqueous sodium bicarbonate, and saturated saline, and dried using magnesium sulfate. After the solvent was distilled off under reduced pressure, the residue was dissolved in tetrahydrofuran-isopropanol (1: 1), 400 mg of cobalt acetate and 1.3 ml of phenylsilane were added, and the mixture was heated to room temperature under an atmosphere of oxygen gas at 1 atm. And stirred for 48 hours. After reducing the reaction mixture, extract with ethyl acetate Issued. The organic phase was washed with saturated aqueous sodium hydrogen carbonate and saturated saline, and dried using magnesium sulfate.
- Example 1 (IS, 4aS, 6R. 7S, 7aR) -6,7_epoxy-7-methyl-1- (methyl carbamoyloxy) -1,4a, 5,7a-tetrahydrocyclopenta described in Step 5 [c] Pyran-4-benzyl carboxylate 1.35 g is dissolved in ethyl acetate, and 60 mg of 5% palladium carbon The catalyst was suspended. The mixture was stirred for 24 hours under an atmosphere of hydrogen gas at 1 atm. After removing insolubles, the filtrate was concentrated. The residue was dissolved in methanol-ether, and trimethylsilyl diazomethane (2.0 M hexane solution) 3.
- CMA cell growth inhibition
- CMA cell migration inhibition
- TFA tube formation inhibition
- the sample solution of the compound used in the MA test was prepared as follows. First, weigh each compound, add the calculated amount of MS0 to dissolve the compound, and obtain a lmg ml sample port in phosphate buffered saline (PBS (-)). PBS (-) was added as above. At this time, the amount of DMS0 to be dissolved in advance was adjusted so that the concentration of DMS0 became%. The resulting solution was diluted 10-fold with 5% DMS0 'PBS (Vatal solution to prepare 0.1 mg ml of sample solution. In the TFA test, 320 mg of the prepared lmg ml sample solution was taken. Add 680/1 PBS (-) to this, A sample for ml was prepared. Further, 100 1 of this solution was taken, PBS (-) 900 / _i1 was added thereto, and the mixture was diluted 10-fold to prepare a sample for lg ml.
- PBS (-) 900 / _i1 was added thereto,
- Human umbilical vein intravenous cells at passage 7 from the primary cells at a cell concentration of 5 x 104 4 ml in a 96-well plate (l waki, Cat # 4860-010) 100 1.
- N 3) Sown.
- M-199 medium containing +20! 3 ⁇ 4FCS, 10 ng ml of b-l''GT, and 10 ng ml of EGF (hereinafter abbreviated as “M199 (2+)”) was used. .
- a double-edged, blade-type power razor was divided into four parts, one of which was sandwiched between forceps and used to peel off the confluent cell surface. Two spots were removed per 1 ⁇ L.
- Cell migration was measured by counting newly migrated cells under a microscope in the range of lramxlmm block. Specifically, as shown in Fig. 1, align the edge of the cell (block) with the line formed when the cells are peeled off, and print the 5x5 (1 cell, 200 zmx200 / In cell m), for example, the number of cells in blocks 1 ⁇ - ⁇ , B, C, D, and E) were all counted to obtain the number of cells in block 1. The total number of cells in the blocks from 1 to 5 was calculated and used as the total cell number. Four visual fields were counted per square inch.
- control (+) indicates the number of migrating cells in the control tube containing M199 (2+).
- type 1-A cell matrix manufactured by Gibco
- 8 volumes 8 volumes
- lOxM-1 volume reconstitution buffer [200 mM HEP 1EPES)
- 0.05 N sodium hydroxide 0.05 N sodium hydroxide
- 260 mM sodium bicarbonate 1 volume gently mixing under ice-cooling so as not to form bubbles, to form a collagen gel.
- This collagen gel is added to a NUNC24 elliptical plate 310 ⁇ 1Z ⁇ The gel was solidified at 37 ° C for 2 hours.
- HUVEC (1 ⁇ 10 5 ml) at passage 7 was seeded at 500 levels from the same primary cells as described above. After culturing at 37 ° C for 2 hours, the cells were cultivated on collagen. Then, after removing the medium by suction, add sample solution 501, then add freshly prepared Kofuken gel at U and P, and incubate at 37 ° C for 1 hour and 10 minutes to solidify the overlay gel.
- sample solution 501 add freshly prepared Kofuken gel at U and P, and incubate at 37 ° C for 1 hour and 10 minutes to solidify the overlay gel.
- the area where the contrast in the center of the well was clear was photographed using ASA400 film, and the obtained photograph was analyzed.
- the length of the formed lumen was measured by using N1H Image of the public domain on a computer.
- the evaluation was performed based on the inhibition rate (%) of tube formation, and the inhibition rate was calculated by the following equation.
- Inhibition rate 100-((Luminated lumen length to which sample was added—Luminal length of control ()) 100 ′ (Luminated length of control (+) — Luminant length of control (-)) )
- a b-FGF inhibitor Protamine
- a collagenase inhibitor Minocycline
- an anti-rheumatic agent Metalmet
- MTX rexetrate
- 5-fluorouracil 5-fluorouracil
- the compounds of the present invention is in] C 5 o value of 100 or more in the case CPA test most despite the absence of cytotoxic effects were observed in the CMA test and TFA tests Was.
- the comparative compounds were all effective in the CMA test and the TFA test, the 1 pulp value in the CPA test was extremely low, and cytotoxicity was observed.
- Compound No. 66 obtained above was converted to colorless powder 67 in the same manner as in Example 2.
- the physicochemical properties of this compound are as described in Table 17, Compound No. 67.
- Compound No. 1-66 obtained above was converted to colorless needles 1-68 in the same manner as in Example 8.
- the physicochemical properties of this compound are as described in Table 17, Compound No.]-68.
- ⁇ -4 obtained above was converted to a colorless powder 1-69 in the same manner as in Example 2.
- the physicochemical properties of this compound are as described in Table 17, Compound No. 1-69.
- Compound ⁇ -150 was produced from Compound No.]-132 in the same manner.
- the physicochemical properties of this compound are described in Tables 30 to 33 and in Compound No. 131 to Compound No. 1-150.
- Netolactol known per se was converted to colorless needles 1-278 (ii0 mg) in the same manner as in Step 4 of Example 1.
- the chemical nature of this compound » is as described in Table 59, Compound No. 1-278.
- Example 35 Compound 14 (500 mg) in Example 35 was dissolved in tetrahydrofuran, and 0.18 ml of methyl chloroformate and 0.27 m: i of triethylamine were added under stirring at -30 ° C. Next, an aqueous solution of 185 mg of hydrogen borohydride was dropped into the above reaction mixture. After the temperature was raised to room temperature, saturated aqueous ammonium chloride was added, and ethyl acetate extraction was performed. The organic phase was washed with saturated saline and dried over magnesium sulfate. After the port compaction, the residue was converted into a colorless oily substance II-15 in the same manner as in Step 1 of Example 18 without purification. The physicochemical properties of this compound are as described in Table 69, Compound No. 1, Table 15.
- Juniperin known per se was converted to colorless needles 287 in the same manner as in Step 4 of Example 1.
- the physicochemical properties of this compound are as described in Table 61, compound No. 287.
- Juniperin known per se was converted to colorless needles 288 by the same method as in Step 4 of Example 1.
- the physicochemical properties of this compound are as described in Table 61, Compound No. 288.
- the compound NI I-17 (2.0 g) described in Example 39 was dissolved in dichloromethane, and 0.83 ml of thionyl chloride was added, followed by stirring at room temperature for 24 hours. Pour the reaction mixture into water and extract with ethyl acetate. Went out. The organic phase was washed with a saturated aqueous solution of sodium bicarbonate and a saturated saline solution, and then dried with magnesium sulfate. After concentration, the residue was dissolved in methyl ethyl ketone without purification, 2.8 g of sodium iodide and 1.6 g of sodium hydrogen carbonate were added, and the mixture was stirred at 60 ° C for 3 hours.
- Example 39 The compound ⁇ . ⁇ -17 (300 rag) described in Example 39 was dissolved in dichloromethane, ethylfurinole ether and pyridinum P-toluenesulfonate were added, and the mixture was stirred at room temperature for 3 hours.
- the reaction mixture was extracted with ethyl acetate. After the organic phase was washed with a saturated saline solution, it was dried with magnesium sulfate. After concentration, the residue was subjected to a hydrolysis reaction in the same manner as in Step 1 of Example 1 without purification. Further, the product obtained by this reaction was converted to a colorless oily substance 301 by a method similar to that of Example 8 without purification.
- the physicochemical properties of this compound are as described in Table 64, Compound No. 1-301.
- the known compound No. 9 shown in Table 74 was converted to a colorless oily substance 1-302 in the same manner as in Example 39.
- the physicochemical properties of this compound are as described in Table 64, Compound No. 1-302.
- the compound extract 302 was converted into a colorless needle 303 by the same method as in step 5 of Example 1.
- the physicochemical properties of this compound are as described in Table 64, Compound Pool 303.
- Compound No. ⁇ -26 was converted to a colorless oil 305 by the same method as in Example 8.
- the physicochemical properties of this compound are as described in Table 64, Compound No. 305.
- Compound No. 1-305 was converted to a colorless powder 1-306 by the same method as in Step 4 of Example 1.
- the physicochemical properties of this compound are as described in Table 64, compound No. 306.
- the compound ⁇ -28 obtained above was converted to a colorless oily substance 1-29 in the same manner as in Step 3 of Example 1.
- the physicochemical properties of this compound are as described in Table 72, Compound No. 29.
- Example 47 Compound No. ⁇ -307 obtained in Example 47 was converted to an amorphous solid 1-310 in the same manner as in Example 7. The physicochemical properties of this compound are described in Table 65, Compound No. 310.
- Example 47 Compound No. 1-307 obtained in Example 47 was converted to an amorphous solid by the same method as in Example 7. -311 was converted to The physicochemical properties of this compound are described in Table 66, Compound No. 1-311.
- Example 47 The compound extract 307 obtained in Example 47 was converted to colorless needles I-312 in the same manner as in Example 4.
- the physicochemical properties of this compound are as described in Table 66, Compound No. 312.
- Example 47 Compound No. 1-307 obtained in Example 47 was converted to amorphous solid 313 in the same manner as in Example 2.
- the physicochemical properties of this compound are described in Table 66, Compound No. 1-313.
- Samples were prepared using the present compounds of Compound Nos. 1-60 to 315. Specifically, take 32 ml of a 20 mM sample solution dissolved in dimethyl sulfoxide (DMS0), make up to 1 ml with phosphate buffered saline (PBS), and adjust the concentration to 0.32 raM (containing 3.2 ° / 6 DMSO). A sample solution was prepared.
- DMS0 dimethyl sulfoxide
- PBS phosphate buffered saline
- 0.32 raM containing 3.2 ° / 6 DMSO
- the double-edged, blade-type force razor was divided into four parts, one of which was sandwiched between forceps, and used to remove the confluent cell surface.
- 125 1 of a PBS solution containing 3.2-dimethyl sulphoxide was added to the control well in place of the sample. After culturing at 37 ° C under 5 ° C02 for 24 hours, the culture solution was discarded, and the cells were fixed with methanol for 30 minutes. Next, after fixing with Giemsa solution for 4 hours, the plate was washed with tap water and air-dried.
- the cell migration was measured by counting the cells that had migrated slightly under a microscope within the range of a li brain X 1 mm block. Specifically, as shown in Fig. 1, the line at the end of the block (block) is aligned with the line formed when the cells are peeled off, and the 5 x 5 (1 block, 200 ra) In the cell of X 200 m), for example, all the cell numbers of block 1 (1-A, B, C, D, E) were counted to obtain the cell number of block 1.
- the total number of cells in blocks from 1 to 5 was calculated, and the total number of cells was determined. Four visual fields were counted per square well.
- the cell migration inhibition rate (3 ⁇ 4) was determined by the following equation.
- Inhibition rate 100-((number of migrated cells to which sample was added-number of cell migration of control (1)) x 100 (number of cell migration of control (+)-number of cell migration of control (1)) number))
- test method for this compound was the same as the test method for the compounds Nos. 1 to 60 described above.
- the angiogenesis inhibitor containing the novel ilide derivative of the present invention as an active ingredient has a remarkable angiogenesis inhibitory action without serious side effects, It is useful for the treatment and prevention of various diseases.
- the compounds of the present invention have excellent solubility and are suitable for use as pharmaceuticals.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97905448A EP0889041B1 (en) | 1996-03-06 | 1997-03-05 | Novel iridoid derivatives and neovascularization inhibitors containing the same as active ingredient |
US09/142,493 US6022888A (en) | 1996-03-06 | 1997-03-05 | Iridoid derivatives and neovascularization inhibitors containing the same as active ingredient |
DE69714230T DE69714230T2 (de) | 1996-03-06 | 1997-03-05 | Neue iridoidderivate und neovaskularisations-inhibitoren die diese als aktviven inhaltstoff enthalten |
AT97905448T ATE221073T1 (de) | 1996-03-06 | 1997-03-05 | Neue iridoidderivate und neovaskularisations- inhibitoren die diese als aktviven inhaltstoff enthalten |
AU22317/97A AU717878B2 (en) | 1996-03-06 | 1997-03-05 | Novel iridoid derivatives and a vascularization inhibitor having for its active ingredient said derivative |
US09/394,510 US6225478B1 (en) | 1997-03-05 | 1999-09-13 | Iridoid derivatives and neovascularization inhibitors containing the same as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8/75419 | 1996-03-06 | ||
JP7541996 | 1996-03-06 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/394,510 Division US6225478B1 (en) | 1997-03-05 | 1999-09-13 | Iridoid derivatives and neovascularization inhibitors containing the same as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997032868A1 true WO1997032868A1 (fr) | 1997-09-12 |
Family
ID=13575660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/000675 WO1997032868A1 (fr) | 1996-03-06 | 1997-03-05 | Nouveaux derives iridoides et inhibiteurs de la neovascularisation contenant ces derives en tant qu'ingredients actifs |
Country Status (9)
Country | Link |
---|---|
US (1) | US6022888A (ja) |
EP (1) | EP0889041B1 (ja) |
KR (1) | KR19990087526A (ja) |
AT (1) | ATE221073T1 (ja) |
AU (1) | AU717878B2 (ja) |
CA (1) | CA2248725A1 (ja) |
DE (1) | DE69714230T2 (ja) |
ES (1) | ES2180936T3 (ja) |
WO (1) | WO1997032868A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1033370A1 (en) * | 1997-11-11 | 2000-09-06 | The Kitasato Institute | Novel substance ft-0554 and process for producing the same |
JP2008106008A (ja) * | 2006-10-26 | 2008-05-08 | Kobayashi Pharmaceut Co Ltd | ゲニポシド酸誘導体 |
US7649014B2 (en) | 2003-03-31 | 2010-01-19 | Beth Israel Deaconess Medical Center, Inc. | Genipin derivatives and uses thereof |
WO2011106448A2 (en) * | 2010-02-23 | 2011-09-01 | Tahitian Noni International, Inc. | Iridoid based formulations |
WO2011106417A2 (en) * | 2010-02-23 | 2011-09-01 | Tahitian Noni International, Inc. | Garcinia mangostana l. and iridoid based formulations |
WO2011106423A2 (en) * | 2010-02-23 | 2011-09-01 | Tahitian Noni International, Inc. | Acai and iridoid based formulations |
WO2011106432A2 (en) * | 2010-02-23 | 2011-09-01 | Tahitian Noni International, Inc. | Morinda citrifolia and iridoid based formulations |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR001000A0 (en) * | 2000-09-08 | 2000-10-05 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
CA2480809A1 (en) * | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
WO2003086382A1 (en) * | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Tnp-470 polymer conjugates and use thereof |
US20050222053A1 (en) * | 2003-10-31 | 2005-10-06 | Health Research, Inc. | Iridoid-saccharide compound and method of using same |
US20080032939A1 (en) * | 2004-10-28 | 2008-02-07 | Health Research, Inc. | Iridoid-saccharide compound and method of using same |
US20080248030A1 (en) * | 2005-02-02 | 2008-10-09 | Children's Medical Center Corporation | Method of Treating Angiogenic Diseases |
WO2009137337A1 (en) * | 2008-05-05 | 2009-11-12 | The Scripps Research Institute | STEREOSELECTIVE SYNTHESIS OF 17-α -AND 17-β -ARYL STEROIDAL COMPOUNDS |
WO2014165023A1 (en) * | 2013-03-12 | 2014-10-09 | Carnegie Mellon University | Coated vaso-occclusive device for treatment of aneurysms |
FR3003860B1 (fr) * | 2013-03-29 | 2015-11-27 | Oreal | Composes derives d'iridoides proteges ou non, composition les comprenant, utilisation comme colorant des fibres keratiniques et dispositifs |
CN104892562B (zh) * | 2015-06-16 | 2017-03-15 | 吴虹 | 抑制环氧化酶‑2的化合物及其制备方法和应用 |
CN107400128B (zh) * | 2017-07-27 | 2020-03-31 | 贵州省中国科学院天然产物化学重点实验室 | 拟单萜吲哚生物碱及其制备方法和应用 |
US20220104839A1 (en) | 2017-10-16 | 2022-04-07 | Retriever Medical, Inc. | Clot Removal Methods and Devices with Multiple Independently Controllable Elements |
US20190110804A1 (en) | 2017-10-16 | 2019-04-18 | Michael Bruce Horowitz | Catheter based retrieval device with proximal body having axial freedom of movement |
US20220104840A1 (en) | 2017-10-16 | 2022-04-07 | Retriever Medical, Inc. | Clot Removal Methods and Devices with Multiple Independently Controllable Elements |
CN115572278B (zh) * | 2022-11-21 | 2023-09-01 | 北京志道生物科技有限公司 | 京尼平衍生物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0276866A (ja) * | 1988-08-12 | 1990-03-16 | Fujisawa Pharmaceut Co Ltd | シクロヘキサン誘導体 |
WO1992006061A1 (en) * | 1990-10-09 | 1992-04-16 | Tsumura & Co. | Iridoide derivative and its use as medicine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1617555C3 (de) * | 1966-04-19 | 1974-09-19 | Kali-Chemie Ag, 3000 Hannover | Verfahren zur Isolierung von therapeutisch wertvollen Isovaleriansäureestern aus Valeriana- und Kentranthus-Extrakten |
US4205083A (en) * | 1968-03-30 | 1980-05-27 | Kali-Chemie Aktiengesellschaft | Cyclopentapyrans |
DE3026579A1 (de) * | 1980-07-14 | 1982-02-11 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 2,9-dioxatricyclo (4,3,1,o(pfeil hoch)3,7(pfeil hoch)) decane |
KR100218052B1 (ko) * | 1992-07-15 | 1999-09-01 | 이병언 | B형 간염 바이러스의 복제를 억제하는 약학적 제제 |
-
1997
- 1997-03-05 AT AT97905448T patent/ATE221073T1/de not_active IP Right Cessation
- 1997-03-05 KR KR1019980706961A patent/KR19990087526A/ko not_active Application Discontinuation
- 1997-03-05 US US09/142,493 patent/US6022888A/en not_active Expired - Fee Related
- 1997-03-05 ES ES97905448T patent/ES2180936T3/es not_active Expired - Lifetime
- 1997-03-05 EP EP97905448A patent/EP0889041B1/en not_active Expired - Lifetime
- 1997-03-05 WO PCT/JP1997/000675 patent/WO1997032868A1/ja not_active Application Discontinuation
- 1997-03-05 DE DE69714230T patent/DE69714230T2/de not_active Expired - Fee Related
- 1997-03-05 AU AU22317/97A patent/AU717878B2/en not_active Ceased
- 1997-03-05 CA CA002248725A patent/CA2248725A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0276866A (ja) * | 1988-08-12 | 1990-03-16 | Fujisawa Pharmaceut Co Ltd | シクロヘキサン誘導体 |
WO1992006061A1 (en) * | 1990-10-09 | 1992-04-16 | Tsumura & Co. | Iridoide derivative and its use as medicine |
Non-Patent Citations (1)
Title |
---|
BEILSTEIN HANDBOOK OF ORGANIC CHEMISTRY, Fifth Supplementary Series, Volume Eighteen Part Six (1987), p. 267. * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1033370A1 (en) * | 1997-11-11 | 2000-09-06 | The Kitasato Institute | Novel substance ft-0554 and process for producing the same |
EP1033370A4 (en) * | 1997-11-11 | 2001-08-08 | Kitasato Inst | NOVEL SUBSTANCE FT-0554 AND MANUFACTURING METHOD |
US6486197B1 (en) | 1997-11-11 | 2002-11-26 | The Kitasato Institute | Substance ft-0554 and process for producing the same |
US7649014B2 (en) | 2003-03-31 | 2010-01-19 | Beth Israel Deaconess Medical Center, Inc. | Genipin derivatives and uses thereof |
US8093288B2 (en) | 2003-03-31 | 2012-01-10 | Beth Israel Deaconess Medical Center | Genipin derivatives and uses thereof |
JP2008106008A (ja) * | 2006-10-26 | 2008-05-08 | Kobayashi Pharmaceut Co Ltd | ゲニポシド酸誘導体 |
WO2011106417A2 (en) * | 2010-02-23 | 2011-09-01 | Tahitian Noni International, Inc. | Garcinia mangostana l. and iridoid based formulations |
WO2011106423A2 (en) * | 2010-02-23 | 2011-09-01 | Tahitian Noni International, Inc. | Acai and iridoid based formulations |
WO2011106432A2 (en) * | 2010-02-23 | 2011-09-01 | Tahitian Noni International, Inc. | Morinda citrifolia and iridoid based formulations |
WO2011106417A3 (en) * | 2010-02-23 | 2012-01-05 | Tahitian Noni International, Inc. | Garcinia mangostana l. and iridoid based formulations |
WO2011106423A3 (en) * | 2010-02-23 | 2012-01-05 | Tahitian Noni International, Inc. | Acai and iridoid based formulations |
WO2011106448A2 (en) * | 2010-02-23 | 2011-09-01 | Tahitian Noni International, Inc. | Iridoid based formulations |
WO2011106432A3 (en) * | 2010-02-23 | 2012-02-02 | Tahitian Noni International, Inc. | Morinda citrifolia and iridoid based formulations |
WO2011106448A3 (en) * | 2010-02-23 | 2012-02-09 | Tahitian Noni International, Inc. | Iridoid based formulations |
Also Published As
Publication number | Publication date |
---|---|
ES2180936T3 (es) | 2003-02-16 |
CA2248725A1 (en) | 1997-09-12 |
AU2231797A (en) | 1997-09-22 |
US6022888A (en) | 2000-02-08 |
KR19990087526A (ko) | 1999-12-27 |
EP0889041A4 (en) | 2000-08-23 |
EP0889041B1 (en) | 2002-07-24 |
AU717878B2 (en) | 2000-04-06 |
DE69714230T2 (de) | 2003-03-27 |
DE69714230D1 (de) | 2002-08-29 |
EP0889041A1 (en) | 1999-01-07 |
ATE221073T1 (de) | 2002-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997032868A1 (fr) | Nouveaux derives iridoides et inhibiteurs de la neovascularisation contenant ces derives en tant qu'ingredients actifs | |
US11858927B2 (en) | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
CN107922423B (zh) | 具有hiv复制抑制作用的含氮三环性衍生物 | |
CN107205970A (zh) | 免疫调节剂 | |
JP2002515497A (ja) | フマジロール誘導体及びその製造方法 | |
CN103517910A (zh) | 作为离子通道调节剂的吗啉-螺环哌啶酰胺 | |
JP2002515498A (ja) | 5−デメトキシフマジロール誘導体及びその製造方法 | |
CN101282725A (zh) | 糖尿病治疗剂 | |
EP1988077A1 (en) | Nirogenous heterocyclic derivatives substituted with cyclic groups | |
CA3042528A1 (en) | Novel phenyl propionic acid derivatives and uses thereof | |
JP2006504621A (ja) | Hivプロテアーゼ阻害剤としてのカルバミン酸エステル | |
KR19980027826A (ko) | 항 b형 간염 바이러스 활성을 갖는 신규한 제니핀 유도체 | |
KR20170090497A (ko) | 디히드로피리미딘-2-온 화합물 및 그의 의약 용도 | |
CN105263924A (zh) | Cxcr7受体调节剂 | |
HU203543B (en) | Process for producing cyclohexane derivatives and pharmaceutical compositions containing them | |
JP2000501111A (ja) | アスパルチルプロテアーゼインヒビター | |
TW200528471A (en) | Dipeptide phenyl ethers | |
CN103987706B (zh) | 吡啶酮衍生物以及含有吡啶酮衍生物的药物 | |
US6225478B1 (en) | Iridoid derivatives and neovascularization inhibitors containing the same as active ingredient | |
JP4762917B2 (ja) | 非ヌクレオシド逆転写酵素インヒビター | |
US20110082133A1 (en) | Pyridone compounds | |
CN118055929A (zh) | 2,6-哌啶二酮类化合物与其应用 | |
US20230026466A1 (en) | Wdr5 inhibitors and modulators | |
EP0717027B1 (en) | Diarylheptanoide derivative and pharmaceutical composition comprising the same | |
TW200827343A (en) | Novel phenylacetic acid derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2248725 Country of ref document: CA Ref country code: CA Ref document number: 2248725 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980706961 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09142493 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997905448 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997905448 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980706961 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997905448 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980706961 Country of ref document: KR |